Hepatitis B Vaccination in Chronic Kidney Disease:- Experience in A Tertiary Care Centre

Background: The study was conducted to examine the seroconversion rate for hepatitis B vaccination in Chronic Kidney Disease (CKD) patients and the factors which influence the sero conversion rate . Methodology: This is a descriptive study which included 235 patients with CKD (chronic kidney disease) with eGFR < 60ml/min/m 2 and they were given 40microgm of Hepatits B vaccine intramuscularly over deltoid at 0,1,2,6 months . Patient characteristics were recorded.Patient response was assessed by measuring antibodies to hepatitis b surface antigen (AntiHBs Ab) six weeks after receiving the 4 th dose. Results : 83% of the patients were seroconverted with titre ≥ 10IU/L .The eGFR and and age are found to influence the titre. Aetiology of CKD and gender has no effect on the sero conversion status. Conclusion: HBV vaccination should be started to CKD patients at the earliest preferably in the first visit itselfas the seroconversion rate declines with progression of CKD.